Eiger BioPharmaceuticals (EIGR) Reports 36% Durable Virologic Response at 24-Wk Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study
Tweet Send to a Friend
Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) today announced end of study post-treatment results of the Phase 2 LIMT HDV Study ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
